Immunohistochemical expression of Cyclin D1 among Sudanese patients diagnosed with benign and malignant prostatic lesions

Autor: Mintu Elsa Chacko, Eman T. Ali, Rowa Hassan, Mohamed S. Muneer, Eiman Siddig Ahmed, Lubna S. Elnour, Ali Mahmoud Mohammed Edris, Nouh S. Mohamed, Mona A. Mohamed, Abdalla Munir, Emmanuel Edwar Siddig
Jazyk: angličtina
Rok vydání: 2020
Předmět:
0301 basic medicine
Male
medicine.medical_specialty
Perineural invasion
Prostatic Hyperplasia
lcsh:Medicine
urologic and male genital diseases
Gastroenterology
General Biochemistry
Genetics and Molecular Biology
Sudan
03 medical and health sciences
Prostate cancer
Prognostic markers
0302 clinical medicine
Cyclin D1
Prostate
Internal medicine
Medicine
Humans
Family history
lcsh:Science (General)
lcsh:QH301-705.5
Aged
Retrospective Studies
Aged
80 and over
business.industry
lcsh:R
Cancer
Prostatic Neoplasms
General Medicine
Hyperplasia
Middle Aged
medicine.disease
Immunohistochemistry
Immunohistochemical expression
Research Note
030104 developmental biology
medicine.anatomical_structure
lcsh:Biology (General)
030220 oncology & carcinogenesis
Histopathology
Neoplasm Grading
business
lcsh:Q1-390
Zdroj: BMC Research Notes, Vol 13, Iss 1, Pp 1-6 (2020)
BMC Research Notes
ISSN: 1756-0500
Popis: Objectives Prostate cancer (PC) is common cancer worldwide. Several markers have been developed to differentiate between benign prostatic hyperplasia (BPH) from PC. A descriptive retrospective hospital-based study aimed at determining the expression of Cyclin D1 in BPH and PC. The study took place at different histopathology laboratories in Khartoum state, Sudan, from December 2016 to January 2019. Formalin-fixed paraffin-embedded blocks were sectioned and fixed in 3-aminopropyltriethoxysilane coated slides incubated into primary antibody for Cyclin D1. The assessment of immunoreactivity of Cyclin D1 of each section was done using the Gleason scoring system. Results A total of 153 males’ prostate sections included in this study, of them, 120 (78.4%) were PC, and 33 (21.6%) were BPH. Their age ranged from 45 to 88 years, mean age was 66.19 ± 8.599. 142 (92.8%) did not have a family history of PC, while 11 (7.2%) patients reported having a family history. The Gleason scoring showed a total of 81 (52.9%) patients with high-grade and 39 (25.5%) with low-grade. 118 (97.5%) patients had PC showed positive results for Cyclin D1, while BPH was 3 (2.5%). P value
Databáze: OpenAIRE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje